Giovanni Camussi, MD

After receiving his MD from the University of Torino (Italy), Dr. Camussi did postdoctoral training in Nephrology at the University of Torino and at Hospital Necker, Paris. He is Professor Emeritus at the Department of Medical Sciences, University of Torino (Italy), and Scientific Coordinator of stem cell research projects of 2i3T Incubator at Molecular Biotechnology Center (University of Torino). Before that, he was a Research Associate Professor of Microbiology and Pathology at the State University of New York at Buffalo, NY (USA), Full Professor of Nephrology at the University of Naples, University of Pavia, and the University of Torino (Italy) where he was President of the School of Medical Biotechnology, Director of the Department of Internal Medicine, Director of the Laboratory of Renal and Vascular Pathophysiology, and he was Adjunct Professor of Medicine, Department of Medicine of Brown University, Providence (RI), USA.

Internationally renowned for 40+ years of research on diabetic nephropathy, renal and liver immunopathology, mediators of tumor and inflammatory angiogenesis, and stem cell biology. He has been named an inventor in 34 patents and has authored over 600 peer-reviewed scientific publications in PubMed-indexed journals (H-index 113 per Google Scholar).

Makoto Kuro-o, MD, Ph.D.

After receiving his MD and Ph.D. from the University of Tokyo, Dr. Kuro-o discovered and named the alpha-Klotho gene in 1997 and has written and published extensively on the topic, opening a new and promising field of research. He moved to the University of Texas Southwestern Medical Center in Dallas, where he was appointed Professor (2012). He then moved back to Japan in 2013 as a Professor at the Division of Anti-aging Medicine Center for Molecular Medicine and a Professor at the Division of Anti-aging Medicine Center for Molecular Medicine at Jichi Medical University.

Dr. Kuro-o has over 30 years of research and clinical experience in endocrinology, endocrine fibroblast growth factors, molecular biology of aging, nephrology, and mineral metabolism, and he has authored over 200 publications (H-index 100 per Google Scholar).

Stephen Michnick, Ph.D.

After receiving his Ph.D. from the University of Toronto, Dr. Michnick did postdoctoral training at the Department of Chemistry at Harvard University with Professors Stuart Schreiber and Martin Karplus (Nobel Prize in Chemistry, 2013). He is currently a Professor of Biochemistry at Université de Montréal, an Adjunct Professor of Bioengineering at McGill University, and a Canada Research Chair in Cell Architecture and Dynamics.

Dr. Michnick’s laboratory studies physical principles governing the organization and properties of macromolecular assemblies in living cells, including the evolution of protein folding and protein-protein interactions. He focuses on how mechan-oactive biomolecular condensates drive functional membrane vesicularization and chromatin organization associated with gene transcription. He is an inventor on 25 patents and has authored over 125 publications (H-index 62 per Google Scholar).

Moosa Mohammadi, Ph.D.

After receiving his Ph.D. in Biochemistry in 1993, Dr. Mohammadi did postdoctoral training at the New York University School of Medicine and became a Professor of Biochemistry and Molecular Pharmacology. He is a Professor at the School of Pharmaceutical Sciences, Wenzhou Medical University, and a Senior Principal Investigator at Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health) in Wenzhou, China.

Dr. Mohammadi is an internationally renowned structural biologist/biochemist with over 30 years of basic research experience focusing on molecular mechanisms of FGF signaling in development and disease. He has authored over 140 publications (H-index 83 per ResearchGate), including two recent high-impact papers in Nature on the FGF23-aKlotho signaling axis. He is an inventor on 15 patents covering a range of FGF-related biologics for various metabolic disorders, including Type 2 diabetes, renal phosphate wasting, chronic kidney disease, and Non-alcoholic fatty liver disease.